Lactobacillus plantarum and Bifidobacterium longum Alleviate Liver Injury and Fibrosis in Mice by Regulating NF-κB and AMPK Signaling
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
In a preliminary study, live biotherapeutic products (LBPs) Lactobacillus plantarum LC27 and Bifidobacterium longum LC67 inhibited the secretion of alanine transaminase (ALT) and aspartate transaminase (AST) in LPS-stimulated HepG2 cells, while Escherichia coli K1 (Ec) increased ALT and ALT secretion. Therefore, we examined the effects of LC27 and LC67 on LPS-induced liver injury and fibrosis in mice and the correlation between their biomarkers in cell and animal experiments. Orally administered LC27 or LC67 significantly decreased blood ALT, AST, γ-glutamyl transferase (γGTP), TNF-α, triglyceride (TG), total cholesterol (TCh), total bile acid, and LPS levels, liver TNF-α, toll-like receptor-4 gene (Tlr4), α-smooth muscle actin (αSMA), and collagen-1 expression and αSMA+ GFAP+ and NF-κB+ F4/80+ cell populations, and colonic Tlr4, TNF-α, and IL-6 expression and NF-κB-positive cell population in LPS-treated mice. Furthermore, they increased AMPKa phosphorylation in the liver and colon. However, Ec increased the expression of TNF-α and IL-6 in blood, liver, and colon. The suppression of LPS-stimulated ALT and AST secretion in HepG2 cells by LBPs was positively correlated with their ameliorating effects on LPS-induced blood γGTP, ALT, and AST levels and liver αSMA and collagen-1 expression in mice. Based on these findings, LC27 and LC67 may improve liver injury and fibrosis by regulating NF-κB and AMPK signaling pathway and a protocol that can assay the inhibitory activity of LBPs on LPS-induced ALT and AST secretion in HepG2 may be useful for guessing their antihepatitic effects in the in vivo experiments.
Abstract
In a preliminary study, live biotherapeutic products (LBPs) Lactobacillus plantarum LC27 and Bifidobacterium longum LC67 inhibited the secretion of alanine transaminase (ALT) and aspartate transaminase (AST) in LPS-stimulated HepG2 cells, while Escherichia coli K1 (Ec) increased ALT and ALT secretion. Therefore, we examined the effects of LC27 and LC67 on LPS-induced liver injury and fibrosis in mice and the correlation between their biomarkers in cell and animal experiments. Orally administered LC27 or LC67 significantly decreased blood ALT, AST, γ-glutamyl transferase (γGTP), TNF-α, triglyceride (TG), total cholesterol (TCh), total bile acid, and LPS levels, liver TNF-α, toll-like receptor-4 gene (Tlr4), α-smooth muscle actin (αSMA), and collagen-1 expression and αSMA+ GFAP+ and NF-κB+ F4/80+ cell populations, and colonic Tlr4, TNF-α, and IL-6 expression and NF-κB-positive cell population in LPS-treated mice. Furthermore, they increased AMPKa phosphorylation in the liver and colon. However, Ec increased the expression of TNF-α and IL-6 in blood, liver, and colon. The suppression of LPS-stimulated ALT and AST secretion in HepG2 cells by LBPs was positively correlated with their ameliorating effects on LPS-induced blood γGTP, ALT, and AST levels and liver αSMA and collagen-1 expression in mice. Based on these findings, LC27 and LC67 may improve liver injury and fibrosis by regulating NF-κB and AMPK signaling pathway and a protocol that can assay the inhibitory activity of LBPs on LPS-induced ALT and AST secretion in HepG2 may be useful for guessing their antihepatitic effects in the in vivo experiments.
참고문헌 (38)
- Konturek PC, "Gut-liver axis : how do gut bacteria influence the liver?", Med. Sci. (Basel), 6, pp.79~ (2018)
- Bawa M, "Gut-liver axis : role of inflammasomes", J. Clin. Exp. Hepatol, 3, pp.141~149 (2013)
- Ohtani N, "Role of the gut-liver axis in liver inflammation, fibrosis, and cancer : a special focus on the gut microbiota relationship", Hepatol. Commun, 3, pp.456~470 (2019)
- Wen L, "Factors influencing the gut microbiota, inflammation, and type 2 diabetes", J. Nutr, 147, pp.1468s~1475s (2017)
- Kociszewska D, "The link between gut dysbiosis caused by a high-fat diet and hearing loss", Int. J. Mol. Sci, 22, pp.13177~ (2021)
- An L, "The role of gut-derived lipopolysaccharides and the intestinal barrier in fatty liver diseases", J. Gastrointest. Surg, 26, pp.671~683 (2022)
- Page MJ, "The role of lipopolysaccharide-induced cell signalling in chronic inflammation", Chronic Stress(Thousand Oaks), 6, pp.24705470221076390~ (2022)
- Luedde T, "NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma", Nat. Rev. Gastroenterol. Hepatol, 8, pp.108~118 (2011)
- Kim SK, "Role of probiotics in human gut microbiome-associated diseases", J. Microbiol. Biotechnol, 29, pp.1335~1340 (2019)
- Mei Z, "The role of probiotics in vaginal health", Front. Cell. Infect. Microbiol, 12, pp.963868~ (2022)
- Williams NT, "Probiotics", Am. J. Health Syst. Pharm, 67, pp.449~458 (2010)
- Abraham BP, "Probiotics in inflammatory bowel disease", Gastroenterol. Clin. North Am, 46, pp.769~782 (2017)
- Borchers AT, "Probiotics and immunity", J. Gastroenterol, 44, pp.26~46 (2009)
- Xia J, "Akkermansia muciniphila ameliorates acetaminophen-induced liver injury by regulating gut microbial composition and metabolism", Microbiol. Spectr, 10, pp.e0159621~ (2022)
- Carpi RZ, "The effects of probiotics, prebiotics and synbiotics in non-alcoholic fat liver disease(NAFLD)and Non-Alcoholic Steatohepatitis(NASH) : A systematic review", Int. J. Mol. Sci, 23, pp.8805~ (2022)
- Gu Z, "Probiotics for alleviating alcoholic liver injury", Gastroenterol. Res. Pract, 2019, pp.9097276~ (2019)
- Lim SM, "Lactobacillus sakei OK67 ameliorates high-fat diet-induced blood glucose intolerance and obesity in mice by inhibiting gut microbiota lipopolysaccharide production and inducing colon tight junction protein expression", Nutr. Res, 36, pp.337~348 (2016)
- Tian F, "Lactobacillus rhamnosus CCFM1107 treatment ameliorates alcoholinduced liver injury in a mouse model of chronic alcohol feeding", J. Microbiol, 53, pp.856~863 (2015)
- Kim WG, "Lactobacillus plantarum LC27 and Bifidobacterium longum LC67 mitigate alcoholic steatosis in mice by inhibiting LPS-mediated NF-κB activation through restoration of the disturbed gut microbiota", Food Funct, 9, pp.4255~4265 (2018)
- In Kim H, "Lactobacillus plantarum LC27 and Bifidobacterium longum LC67simultaneously alleviate high-fat diet-induced colitis, endotoxemia, liver steatosis, and obesity in mice", Nutr. Res, 67, pp.78~89 (2019)
- Jang SE, "Simultaneous amelioration of colitis and lver ijury in mce by Bifidobacterium longum LC67 and Lactobacillus plantarum LC27", Sci. Rep, 8, pp.7500~ (2018)
- Wang Q, "Lactobacillus helveticus R0052 alleviates liver injury by modulating gut microbiome and metabolome in D-galactosamine-treated rats", Appl. Microbiol. Biotechnol, 103, pp.9673~9686 (2019)
- Shu X, "Bifidobacterium lactis TY-S01 protects against alcoholic liver injury in mice by regulating intestinal barrier function and gut microbiota", Heliyon, 9, pp.e17878~ (2023)
- Chang B, "The protective effect of VSL#3 on intestinal permeability in a rat model of alcoholic intestinal injury", BMC Gastroenterol, 13, pp.151~ (2013)
- Lee DY, "Alleviation of cognitive impairment by gut microbiota lipopolysaccharide production-suppressing Lactobacillus plantarum and Bifidobacterium longum in mice", Food Funct, 12, pp.10750~10763 (2021)
- Jang HM, "Evidence for interplay among antibacterial-induced gut microbiota disturbance, neuro-inflammation, and anxiety in mice", Mucosal. Immunol, 11, pp.1386~1397 (2018)
- Kim JK, "Interplay between human gut bacteria Escherichia coli and Lactobacillus mucosae in the occurrence of neuropsychiatric disorders in mice", Front. Immunol, 11, pp.273~ (2020)
- Chiba T, "Inflammation-associated cancer development in digestive organs : mechanisms and roles for genetic and epigenetic modulation", Gastroenterology, 143, pp.550~563 (2012)
- Chen L, "Inflammatory responses and inflammation-associated diseases in organs", Oncotarget, 9, pp.7204~7218 (2018)
- Agirman G, "Signaling inflammation across the gut-brain axis", Science, 374, pp.1087~1092 (2021)
- Nishida A, "Gut microbiota in the pathogenesis of inflammatory bowel disease", Clin. J. Gastroenterol, 11, pp.1~10 (2018)
- Tlaskalová-Hogenová H, "Commensal bacteria(normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases", Immunol. Lett, 93, pp.97~108 (2004)
- Candelli M, "Interaction between lipopolysaccharide and gut microbiota in inflammatory bowel diseases", Int. J. Mol. Sci, 22, pp.6242~ (2021)
- Jang SE, "Gastrointestinal inflammation by gut microbiota disturbance induces memory impairment in mice", Mucosal. Immunol, 11, pp.369~379 (2018)
- Fukui H, "Gut-liver axis in liver cirrhosis : How to manage leaky gut and endotoxemia", World J. Hepatol, 7, pp.425~442 (2015)
- Keshavarz Azizi Raftar S, "The protective effects of live and pasteurized Akkermansia muciniphila and its extracellular vesicles against HFD", CCl4-induced liver injury, 2021, pp.9, e0048421~
- Chen Y, "Lactobacillus plantarum Lp2 improved LPS-induced liver injury through the TLR-4", MAPK, CYP2E1 pathways in mice, pp.Food Nutr. Res, 2022[DOI]
- Chiu YH, "Lactobacillus casei MYL01 modulates the proinflammatory state induced by ethanol in an in vitro model", J. Dairy Sci, 97, pp.2009~2016 (2014)